- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00198328
Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Base of the Tongue, Posterior Lateral Pharyngeal Wall, Hypopharynx, or Larynx That Have Failed Primary Curative Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recurrent tumors in head and neck squamous cell carcinoma usually have a poor prognosis. In patients suitable for salvage surgery of their recurrent disease, the success rate for local control has been reported to be 40-50%. The surgical treatment of H&N SCC frequently results in significant loss of organ function (e.g., inability to swallow, speak, etc.) and/or permanent disfigurement. There is a compelling and unmet medical need for a local therapy that destroys tumors while preserving function status and appearance in patients with primary, recurrent, or metastatic H&N SCC.
Comparison: To compare function status at 4 months after treatment with bleomycin-EPT or surgery in patients with locally recurrent or second primary SCC of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx or larynx that have failed primary curative therapy and in whom surgical resection is seen as an option for disease control.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- Inovio Biomedical Corporation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The presence of SCC of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx, or larynx must be confirmed by histological examination of a tissue sample (e.g., biopsy) obtained within 1 month of the patient receiving the study treatment.
- Recurrent or second primary disease in patients where surgical resection is seen as an option for disease control.
- The length of the longest diameter of the study lesion must be < 5 cm and the calculated treatment volume must be < 60.0 cm3 (tumor volume plus a 0.5 cm margin around the tumor) for the study lesion [where treatment volume = 0.5 (A+1) (B+1)2 and where A = length of the longest diameter (cm), B = the next longest diameter perpendicular to "A" (cm)].
- Tumor burden must be completely encompassed by surgery or bleomycin-EPT.
- Age: 18 years or older.
- Men and women of childbearing potential must use physician approved contraceptive methods for 7 days following bleomycin-EPT.
Hematopoietic status:
- Absolute neutrophil count (ANC) > 1000/uL
- Platelets > 75,000/mm3
- Prothrombin time: international normalized ratio (PT: INR) 1.5 (correctable with vitamin K injection)
Blood chemistry status:
- Transaminases < 3 times upper limit of normal
- Total bilirubin < 2.5 mg/dL
- Creatinine < 2.5mg/dL
- A written Informed Consent form must be signed prior to the patient receiving any study procedures or treatments.
Exclusion Criteria:
- Patients with tumors suspected of involving a 50% or greater encasement of a blood vessel as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
- Patients with tumors having bone invasion.
- Patients with any metallic implants in the treatment field.
- Patients with hypersensitivity to bleomycin.
- Patients who have received or will exceed a total lifetime dose of bleomycin greater than 400 units.
- Patients deemed unsuitable for general anesthesia.
- Patients with a significant history of emphysema or pulmonary fibrosis.
- Patients with indwelling cardiac pacemakers who cannot tolerate a period with pacemaker turned off.
- Patients with a history of uncontrolled cardiac arrhythmia.
- Women who are pregnant, or are nursing. Women of childbearing potential must have a negative beta human chorionic gonadotropin (beta hCG) test within 7 days of study treatment.
- Radiation therapy to the treatment area within 8 weeks of study treatment.
- Chemotherapy or other cancer therapy (e.g., surgery, cryotherapy, etc.) to the treatment area within 4 weeks of study treatment.
- Patients participating in a clinical study for an investigational drug or device within 4 weeks prior to the study treatment.
- Patients previously randomized to this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Surgery Control
Patients receive surgical excision of their tumor.
|
Patients have their tumor surgically removed.
|
Experimental: MedPulser EPT
Patients receive electroporation with injection of Bleomycin Sulfate.
|
Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Function status at 4 months using the performance status scale for head and neck cancer (PSSHN) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck (EORTC-QLC-H&N35)
Time Frame: 4 Months
|
4 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Local tumor recurrence, disease free survival and overall survival rates through 2 years after bleomycin-EPT or surgery treatment
Time Frame: 4 Months
|
4 Months
|
Safety through 6 months after the study treatment
Time Frame: 6 Months
|
6 Months
|
Durability of function status outcomes at 8 months after bleomycin-EPT or surgery treatment
Time Frame: 8 Months
|
8 Months
|
Pharmacoeconomic parameters through 8 months after bleomycin-EPT or surgery treatment
Time Frame: 8 Months
|
8 Months
|
Bleomycin systemic absorption and plasma pharmacokinetics following intratumoral (IT) bleomycin-EPT administration
Time Frame: 96 Hours
|
96 Hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HNBE-03-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on Surgical Excision
-
University Hospital Inselspital, BerneCompleted
-
Sohag UniversityRecruitingSpinal Cord TumorEgypt
-
Lawson Health Research InstituteNot yet recruitingBreast Fibroadenoma | Lobular Carcinoma in Situ | Atypical Ductal Hyperplasia | Phyllodes Breast Tumor | Atypical Lobular Hyperplasia | Flat Epithelial Atypia | Phyllodes; Fibroadenoma | Radial Scar | Breast Papilloma | Complex Sclerosing Papillary Lesion of the Breast
-
Sohag UniversityActive, not recruiting
-
Peking Union Medical College HospitalCompleted
-
Semmelweis UniversityRecruitingRecurrence | Periodontal; Lesion | Localized Gingival Enlargement | EpulidesHungary
-
Stanford UniversityRecruitingPilonidal DiseaseUnited States
-
Assiut UniversityUnknownManagement of Intracranial Cavernous Hemangioma
-
Kasr El Aini HospitalUnknownNeurocognitive Outcome Assesment in Patients With Perioptic Meningiomas
-
Domain Surgical, Inc.Withdrawn